Transactions of Managers and Closely Associated Persons
Attached are copies of two filings with the Luxembourg Commission de Surveillance…
Alvotech further strengthens liquidity by securing term loan facility of $75 million
July 01, 2026 04:00 ET | Source: Alvotech — $75 million additional…
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio
REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global…
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
May 11, 2026 04:30 ET | Source: Alvotech Company remains on track…
Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed…
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published…
Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma
Introduction of AVT05 supported by NHS England tender award in the United…
Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a…
Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for…
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25,…
